Is MDXG or MGX more undervalued in 2026?

CirclFi compares MiMedx Group, Inc (MDXG) and Metagenomi Therapeutics, Inc. (MGX) using 13 institutional-grade valuation models. MDXG has a Quality of Company score of 8.6/10 while MGX scores 5.0/10.

Which is a better buy — MDXG or MGX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MDXG and MGX valuations compare?

MDXG at $3.67 and MGX at $1.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MDXG vs MGX Valuation Comparison 2026 — Intrinsic Value Analysis

MDXG

Biotechnology

MiMedx Group, Inc

Quality

8.6

out of 10

Value Trap

SAFE

Price

$3.67

Last close

Models

13/13

Active

MGX

Biotechnology

Metagenomi Therapeutics, Inc.

Quality

5.0

out of 10

Value Trap

SAFE

Price

$1.40

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	MDXG Fair Value	MDXG Upside	MGX Fair Value	MGX Upside
Bayesian DCF	Intrinsic	$6.90	+88.1%	$0.27	-80.5%
Earnings Power Value	Intrinsic	$1.47	-59.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.30	-64.5%	$3.20	+128.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MDXG vs MGX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MDXG vs MGX — Which Stock Is More Undervalued?

MDXG scores higher with a 8.6/10 quality rating vs MGX's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MiMedx Group, Inc (MDXG) and Metagenomi Therapeutics, Inc. (MGX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MDXG currently trades at $3.67 with a QOC of 8.6/10, while MGX trades at $1.40 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).